237 related articles for article (PubMed ID: 24992895)
1. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.
Takahashi R; Ishibashi Y; Hiraoka K; Matsueda S; Kawano K; Kawahara A; Kage M; Ohshima K; Yamanaka R; Shichijo S; Shirouzu K; Itoh K; Sasada T
Cancer Sci; 2013 Oct; 104(10):1285-94. PubMed ID: 23829867
[TBL] [Abstract][Full Text] [Related]
3. Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer.
Toh U; Sakurai S; Saku S; Takao Y; Okabe M; Iwakuma N; Shichijo S; Yamada A; Itoh K; Akagi Y
Cancer Sci; 2020 Aug; 111(8):2760-2769. PubMed ID: 32495455
[TBL] [Abstract][Full Text] [Related]
4. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.
Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Sasada T; Hattori N; Kohno N; Itoh K
Cancer Sci; 2015 Oct; 106(10):1257-63. PubMed ID: 26212219
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
Matsumoto K; Noguchi M; Satoh T; Tabata K; Fujita T; Iwamura M; Yamada A; Komatsu N; Baba S; Itoh K
BJU Int; 2011 Sep; 108(6):831-8. PubMed ID: 21166757
[TBL] [Abstract][Full Text] [Related]
6. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
Kawano K; Tsuda N; Matsueda S; Sasada T; Watanabe N; Ushijima K; Yamaguchi T; Yokomine M; Itoh K; Yamada A; Kamura T
Immunopharmacol Immunotoxicol; 2014 Jun; 36(3):224-36. PubMed ID: 24773550
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
[TBL] [Abstract][Full Text] [Related]
8. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens.
Yamada T; Terazaki Y; Sakamoto S; Yoshiyama K; Matsueda S; Komatsu N; Waki K; Yamada A; Kawahara A; Kage M; Sugawara S; Yamashita Y; Sasada T; Takamori S; Itoh K
Int J Oncol; 2015 Jan; 46(1):55-62. PubMed ID: 25310280
[TBL] [Abstract][Full Text] [Related]
9. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
Sakamoto S; Yutani S; Shichijo S; Morita M; Yamada A; Itoh K; Noguchi M
Cancer Immunol Immunother; 2016 Oct; 65(10):1223-31. PubMed ID: 27549314
[TBL] [Abstract][Full Text] [Related]
10. [Development of Peptide Vaccines for Triple-Negative Breast Cancer Treatment].
Toh U; Saku S; Okabe M; Iwakuma N; Kimitsuki Y; Akashi M; Ogo E; Yamada A; Shichijo S; Itoh K; Akagi Y
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1249-1251. PubMed ID: 27760950
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
[TBL] [Abstract][Full Text] [Related]
13. Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.
Sakamoto S; Yamada T; Terazaki Y; Yoshiyama K; Sugawara S; Takamori S; Matsueda S; Shichijo S; Yamada A; Noguchi M; Itoh K; Hattori N; Kohno N; Sasada T
Clin Lung Cancer; 2017 Nov; 18(6):e385-e394. PubMed ID: 28416261
[TBL] [Abstract][Full Text] [Related]
14. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
Chick RC; Clifton GT; Hale DF; Vreeland TJ; Hickerson AT; Kemp Bohan PM; McCarthy PM; Litton JK; Alatrash G; Murthy RK; Qiao N; Philips A; Lukas J; Holmes JP; Mittendorf EA; Peoples GE
Clin Immunol; 2021 Apr; 225():108679. PubMed ID: 33485895
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K
J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
[TBL] [Abstract][Full Text] [Related]
18. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
[TBL] [Abstract][Full Text] [Related]
19. Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.
Kawano K; Tsuda N; Waki K; Matsueda S; Hata Y; Ushijima K; Itoh K; Yamada A; Kamura T
Cancer Sci; 2015 Sep; 106(9):1111-7. PubMed ID: 26122553
[TBL] [Abstract][Full Text] [Related]
20. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11
Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Naitou M; Sasada T; Hattori N; Kohno N; Itoh K
Cancer Sci; 2017 Apr; 108(4):598-603. PubMed ID: 28178396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]